65. Primary immunodeficiency Clinical trials / Disease details

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2031200236	28/09/2017	10/12/2020	Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis	Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis	chronic granulomatous disease-associated colitis primary immunodeficiency diseases; inflammatory bowel disease;D006105	1) Oral administration of thalidomide (1.5-3mg/kg), once a day 2) Oral administration of placebo (1.5-3mg/kg), once a day	Kawai Toshinao	Kawai Toshinao;Japan Agency for Medical Research and Development	Recruiting	>= 1age old	Not applicable	Both	8	Phase 2-3	Japan
2	JPRN-UMIN000029324	2017/09/28	01/10/2017	Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis	Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis - Clinical trial of thalidomide for CGD colitis	Chronic granulomatous disease associated colitis	Oral administration of thalidomide (1.5-3mg/kg), once a day Oral administration of placebo (1.5-3mg/kg), once a day	National Center for Child Heath and Development	NULL	Recruiting	1years-old	Not applicable	Male and Female	8	Not selected	Japan
3	JPRN-UMIN000009370	2012/12/07	21/11/2012	Thalidomide therapy clinical trial for chronic granulomatous disease-associated intractable granulomatous lesion	Thalidomide therapy clinical trial for chronic granulomatous disease-associated intractable granulomatous lesion - Thalidomide therapy for chronic granulomatous disease	Chronic granulomatous disease	Oral administration of thalidomide	National Center for Child Heath and Development	NULL	Complete: follow-up complete	3years-old	Not applicable	Male and Female	5	Not selected	Japan